Comparative Pharmacology
Head-to-head clinical analysis: ISMOTIC versus MANNITOL 20 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISMOTIC versus MANNITOL 20 IN PLASTIC CONTAINER.
ISMOTIC vs MANNITOL 20% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosmotic solution of mannitol; increases plasma osmolality, drawing water from tissues into the vasculature and reducing intracranial/intraocular pressure via osmotic diuresis.
Mannitol is an osmotic diuretic that increases plasma osmolality, drawing water from intracellular compartments into extracellular fluid. In the kidneys, it is freely filtered at the glomerulus but minimally reabsorbed, increasing tubular fluid osmolality and reducing water reabsorption, thereby promoting diuresis. It also reduces cerebral edema by creating an osmotic gradient that draws water from brain tissue into plasma.
1-2 g orally every 6-8 hours, maximum 8 g/day; or 1-2 g intravenously over 5-10 minutes every 6-8 hours, maximum 8 g/day.
Intravenous: 50-100 g (250-500 mL of 20% solution) over 30-60 minutes; may repeat every 6-8 hours as needed. For cerebral edema: 1-2 g/kg IV over 30-60 minutes.
None Documented
None Documented
4.5-6.0 hours in adults with normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria)
Terminal elimination half-life: 0.25–1.7 hours in normal renal function; prolonged in renal impairment.
Renal: 90-95% unchanged; biliary/fecal: <5%
Renal: >90% as unchanged drug. Biliary/fecal: negligible.
Category C
Category A/B
Osmotic Diuretic
Osmotic Diuretic